-

05:56:41 AM

ATRS Stock News

ATRS - Antares Pharma Inc

05/12/22 8:00 AM

Nasdaq : ATRS, HALO

acquisition

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma,

RHEA-AI

neutral

04/13/22 5:41 PM

Nasdaq : ATRS, OBNK, SRRA

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNK

Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:Sierra Oncology , Inc. (NASDAQ: SRRA)'s sale to

RHEA-AI

neutral

04/13/22 8:08 AM

Nasdaq : ATRS

ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. to Halozyme Therapeutics, Inc. for $5.60 per share in cash is fair to Antares Pharma shareholders. Halper Sadeh encourages Antares Pharma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper...

RHEA-AI

neutral

04/13/22 6:00 AM

Nasdaq : HALO, ATRS

acquisition

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and BeyondAugments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing PotentialDiversifies Revenue Mix

RHEA-AI

very positive

03/29/22 7:00 AM

Nasdaq : ATRS

fda approval

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate),

RHEA-AI

very positive

03/03/22 7:00 AM

Nasdaq : ATRS

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE

RHEA-AI

positive

02/28/22 8:30 AM

Nasdaq : ATRS

conferences

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42 nd

RHEA-AI

neutral

02/17/22 8:30 AM

Nasdaq : ATRS

conferences

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.

RHEA-AI

neutral

02/03/22 8:00 AM

Nasdaq : ATRS

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”)

RHEA-AI

very positive

01/18/22 7:30 AM

Nasdaq : ATRS

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The development

RHEA-AI

very positive

1 2 3 4 5 6 Next

ATRS Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.antarespharma.com
CeoRobert Apple
Security nameAntares Pharma Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees185
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
AddressSuite 300
Address2100 Princeton South
StateNew Jersey
CityEwing
Zip08628
CountryUS
Phone16093593020

About Antares Pharma Inc

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.